Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial - Albiges, L; Tannir, NM; Burotto, M (ESMO Open, 2020)
et al.